Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2015

Date: September 16, 2015
Pages: 82
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AA0BA54696DEN
Leaflet:

Download PDF Leaflet

Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2015’, provides an overview of the Allergic Rhino-Conjunctivitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Allergic Rhino-Conjunctivitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Allergic Rhino-Conjunctivitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Allergic Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Allergic Rhino-Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Allergic Rhino-Conjunctivitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Allergic Rhino-Conjunctivitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Allergic Rhino-Conjunctivitis Overview
Therapeutics Development
Pipeline Products for Allergic Rhino-Conjunctivitis - Overview
Allergic Rhino-Conjunctivitis - Therapeutics under Development by Companies
Allergic Rhino-Conjunctivitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Allergic Rhino-Conjunctivitis - Products under Development by Companies
Allergic Rhino-Conjunctivitis - Companies Involved in Therapeutics Development
ALK-Abello A/S
Allergopharma Joachim Ganzer KG
Allergy Therapeutics Plc
Bial - Portela & Ca, S.A.
BioTech Tools s.a.
Circassia Pharmaceuticals Plc
Greer Laboratories, Inc.
HAL Allergy BV
Immunomic Therapeutics, Inc.
Laboratorios LETI S.L.
Oxagen Limited
Stallergenes S.A.
Allergic Rhino-Conjunctivitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AL-0704rP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergen for Cupressus Arizonica Pollen Induced Allergic Rhino-Conjunctivitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergen for Salsola Kali Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergovac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP-4070 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gp-ASIT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-8237 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OC-000459 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Olea Europaea Pollen Extract - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pollinex Quattro Grass - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ragweed Pollen Extract - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rBet v1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rBet v1-FV - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rPhleum - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Allergic Rhino-Conjunctivitis and House Dust Mite Allergy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Asthma, Grass Pollen Allergy and Allergic Rhino-Conjunctivitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergic Rhino-Conjunctivitis - Recent Pipeline Updates
Allergic Rhino-Conjunctivitis - Dormant Projects
Allergic Rhino-Conjunctivitis - Discontinued Products
Allergic Rhino-Conjunctivitis - Product Development Milestones
Featured News & Press Releases
Jun 09, 2014: ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen
May 18, 2014: BioTech Tools will be present at the EAACI congress
Mar 10, 2014: GREER Investigational Sublingual Allergy Immunotherapy Liquid (SAIL) for Short Ragweed Allergies Phase III Data Published in Journal of Allergy and Clinical Immunology
Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics
Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites
Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Allergic Rhino-Conjunctivitis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd.1)
Allergic Rhino-Conjunctivitis - Pipeline by ALK-Abello A/S, H2 2015
Allergic Rhino-Conjunctivitis - Pipeline by Allergopharma Joachim Ganzer KG, H2 2015
Allergic Rhino-Conjunctivitis - Pipeline by Allergy Therapeutics Plc, H2 2015
Allergic Rhino-Conjunctivitis - Pipeline by Bial - Portela & Ca, S.A., H2 2015
Allergic Rhino-Conjunctivitis - Pipeline by BioTech Tools s.a., H2 2015
Allergic Rhino-Conjunctivitis - Pipeline by Circassia Pharmaceuticals Plc, H2 2015
Allergic Rhino-Conjunctivitis - Pipeline by Greer Laboratories, Inc., H2 2015
Allergic Rhino-Conjunctivitis - Pipeline by HAL Allergy BV, H2 2015
Allergic Rhino-Conjunctivitis - Pipeline by Immunomic Therapeutics, Inc., H2 2015
Allergic Rhino-Conjunctivitis - Pipeline by Laboratorios LETI S.L., H2 2015
Allergic Rhino-Conjunctivitis - Pipeline by Oxagen Limited, H2 2015
Allergic Rhino-Conjunctivitis - Pipeline by Stallergenes S.A., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Allergic Rhino-Conjunctivitis Therapeutics - Recent Pipeline Updates, H2 2015
Allergic Rhino-Conjunctivitis - Dormant Projects, H2 2015
Allergic Rhino-Conjunctivitis - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Allergic Rhino-Conjunctivitis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

ALK-Abello A/S
Allergopharma Joachim Ganzer KG
Allergy Therapeutics Plc
Bial - Portela & Ca, S.A.
BioTech Tools s.a.
Circassia Pharmaceuticals Plc
Greer Laboratories, Inc.
HAL Allergy BV
Immunomic Therapeutics, Inc.
Laboratorios LETI S.L.
Oxagen Limited
Stallergenes S.A.
Skip to top


Rhino-Conjunctivitis - Pipeline Review, H1 2016 US$ 2,000.00 Jun, 2016 · 90 pages
Rhino - Conjunctivitis - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Bacterial Conjunctivitis - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 61 pages

Ask Your Question

Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: